Humana Inc. (NYSE:HUM) Shares Sold by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC cut its stake in shares of Humana Inc. (NYSE:HUM) by 20.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,923 shares of the insurance provider’s stock after selling 485 shares during the period. Sequoia Financial Advisors LLC’s holdings in Humana were worth $488,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. FPC Investment Advisory Inc. acquired a new position in Humana during the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC acquired a new position in shares of Humana during the fourth quarter worth $30,000. OFI Invest Asset Management purchased a new position in Humana in the fourth quarter valued at $33,000. Atwood & Palmer Inc. raised its stake in Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares in the last quarter. Finally, Kestra Investment Management LLC purchased a new stake in Humana during the 4th quarter worth about $49,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Performance

NYSE:HUM opened at $269.86 on Wednesday. The firm has a market cap of $32.57 billion, a price-to-earnings ratio of 27.12, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The firm’s fifty day moving average price is $271.45 and its 200 day moving average price is $278.29.

Humana (NYSE:HUM) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, sell-side analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.31%. Humana’s dividend payout ratio is currently 35.58%.

Insider Activity at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.37% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on HUM. StockNews.com downgraded Humana from a “buy” rating to a “hold” rating in a report on Tuesday. Piper Sandler increased their price target on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Truist Financial upped their target price on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. JPMorgan Chase & Co. cut their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $290.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.